Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$2.75B |
| 2 |
Coupang
CPNG
|
$1.09B |
| 3 |
Trade Desk
TTD
|
$793M |
| 4 |
BioNTech
BNTX
|
$736M |
| 5 |
Bilibili
BILI
|
$639M |
Top Sells
| 1 |
Tesla
TSLA
|
$7.41B |
| 2 |
Alphabet (Google) Class C
GOOG
|
$1.39B |
| 3 |
Meta Platforms (Facebook)
META
|
$880M |
| 4 |
Amazon
AMZN
|
$773M |
| 5 |
NIO
NIO
|
$619M |
Sector Composition
| 1 | Consumer Discretionary | 31.93% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 17.13% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Agios Pharmaceuticals
AGIO
$2.09B
| $10K | ﹤0.01% |
186
+3
| +2% | +$161 |
|
402
Columbia Sportswear
COLM
$3.09B
| $10K | ﹤0.01% |
95
-5
| -5% | -$526 |
|
|
GAN
403
DELISTED
GAN Ltd
GAN
| $10K | ﹤0.01% |
+572
| New | +$10K |
|
404
Gen Digital
GEN
$18.2B
| $10K | ﹤0.01% |
462
-18
| -4% | -$390 |
|
405
Ironwood Pharmaceuticals
IRWD
$188M
| $10K | ﹤0.01% |
935
-55
| -6% | -$588 |
|
406
Robert Half
RHI
$3.77B
| $10K | ﹤0.01% |
132
-3
| -2% | -$227 |
|
407
Yelp
YELP
$2.02B
| $10K | ﹤0.01% |
262
+11
| +4% | +$420 |
|
|
TWOU
408
DELISTED
2U, Inc.
TWOU
| $10K | ﹤0.01% |
9
-1
| -10% | -$1.11K |
|
|
POLY
409
DELISTED
Plantronics, Inc.
POLY
| $10K | ﹤0.01% |
254
+20
| +9% | +$787 |
|
410
Calavo Growers
CVGW
$485M
| $9K | ﹤0.01% |
113
-9
| -7% | -$717 |
|
411
Equifax
EFX
$30.8B
| $9K | ﹤0.01% |
52
+9
| +21% | +$1.56K |
|
412
Ziff Davis
ZD
$1.56B
| $9K | ﹤0.01% |
84
-5
| -6% | -$536 |
|
|
MDP
413
DELISTED
Meredith Corporation
MDP
| $9K | ﹤0.01% |
293
-27
| -8% | -$829 |
|
414
C3.ai
AI
$2.15B
| $8K | ﹤0.01% |
+117
| New | +$8K |
|
415
Anterix
ATEX
$412M
| $8K | ﹤0.01% |
162
| – | – |
|
416
CarGurus
CARG
$3.59B
| $8K | ﹤0.01% |
345
+13
| +4% | +$301 |
|
417
Cognyte Software
CGNT
$657M
| $8K | ﹤0.01% |
+303
| New | +$8K |
|
418
Cimpress
CMPR
$1.54B
| $8K | ﹤0.01% |
84
+4
| +5% | +$381 |
|
419
Hillenbrand
HI
$1.85B
| $8K | ﹤0.01% |
170
+3
| +2% | +$141 |
|
420
Modine Manufacturing
MOD
$7.1B
| $8K | ﹤0.01% |
558
| – | – |
|
421
Telus
TU
$25.3B
| $8K | ﹤0.01% |
397
-2
| -0.5% | -$40 |
|
422
John Wiley & Sons Class A
WLY
$2.13B
| $8K | ﹤0.01% |
153
-6
| -4% | -$314 |
|
|
XENT
423
DELISTED
Intersect ENT, Inc
XENT
| $8K | ﹤0.01% |
361
+21
| +6% | +$465 |
|
424
Cerus
CERS
$255M
| $7K | ﹤0.01% |
1,143
-46
| -4% | -$282 |
|
425
Inogen
INGN
$219M
| $7K | ﹤0.01% |
141
-8
| -5% | -$397 |
|